Sanofi will pay $260 million to exit a diabetes drug collaboration with Lexicon Pharmaceuticals, settling a dispute that arose when the French pharma provided notice to Lexicon in July that it would end the partnership. As a result, Lexicon will regain all rights to Zynquista, a drug approved in Europe for Type 1 diabetes. Money received from Sanofi will be used to fund ongoing development of drug, Lexicon said.  Sanofi’s decision to pull back was prompted by mixed results from three Phase 3 studies of Zynquista in Type 2 diabetes, two of which showed blood sugar lowering that missed trial goals. Learn More